AVIGEN INC \DE
10-Q, EX-27, 2000-11-09
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: AVIGEN INC \DE, 10-Q, 2000-11-09
Next: CENTURY CAPITAL MANAGEMENT INC / MASSACHUSETTS, 13F-HR, 2000-11-09



<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          JUN-30-2001
<PERIOD-START>                             JUL-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                           1,199
<SECURITIES>                                    72,167
<RECEIVABLES>                                    1,631
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                74,997
<PP&E>                                           9,444
<DEPRECIATION>                                   3,072
<TOTAL-ASSETS>                                  83,605
<CURRENT-LIABILITIES>                            1,984
<BONDS>                                          5,104
                                0
                                          0
<COMMON>                                            17
<OTHER-SE>                                      76,500
<TOTAL-LIABILITY-AND-EQUITY>                    83,605
<SALES>                                              0
<TOTAL-REVENUES>                                    30
<CGS>                                                0
<TOTAL-COSTS>                                    4,293
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                  35
<INCOME-PRETAX>                                (3,049)
<INCOME-TAX>                                         3
<INCOME-CONTINUING>                            (3,052)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (3,052)
<EPS-BASIC>                                   (0.18)
<EPS-DILUTED>                                   (0.18)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission